Perceptive Discovery Enhances Preclinical Capabilities
Perceptive Discovery has announced an investment of $15 million aimed at bolstering its preclinical and translational services. This initiative reflects the company's commitment to advancing its radiochemistry, cell assay, and in vitro capabilities. The backing from CapVest Partners LLP illustrates strong confidence in the growth potential of Perceptive Discovery.
Expanding Astatine-211 Infrastructure
A key part of the strategic investment involves expanding Perceptive Discovery's infrastructure for Astatine-211 (At-211). This expansion will occur at two primary locations in the U.S. and U.K., where new systems and dedicated scientific professionals will enhance the company's offerings. The goal is to effectively support the increasing demand for alpha-emitting isotopes that are essential for innovative radioligand therapy (RLT) advancements.
Innovating Cell Assay Development
Alongside the advancements in radiochemistry, Perceptive Discovery is excited to announce improvements in its cell assay development capabilities. The addition of in-house hot assay development will create a streamlined scientific workflow that integrates assay development, characterization, and downstream evaluation. This enhancement enables Perceptive Discovery to provide a more comprehensive suite of services, aligning closely with the needs of sponsors involved in oncology research.
Upgrading In-Vitro Biology Facility
As part of the strategic investments, Perceptive Discovery is also upgrading its in vitro biology facility, which has been a cornerstone of its research infrastructure. The newly enhanced facility will provide increased laboratory space, state-of-the-art equipment, and additional expert personnel. This expansion is pivotal for ensuring high-quality tumor growth research and offering a broader range of assay platforms that adapt to evolving sponsor needs.
Commitment to Quality and Efficiency
Ben Murphy, the Chief Executive Officer of Perceptive Discovery, stated that these investments reflect a dedication to understanding and meeting the evolving needs of their partners. The ongoing enhancement of their integrated preclinical workflows—spanning radiochemistry, cell assays, and in vitro capabilities—positions the company to provide invaluable data from the discovery phase through early clinical translation. With the strong support from CapVest, Perceptive Discovery is poised to deliver enhanced services and innovation.
Building a Leading Value Proposition
Perceptive Discovery aims to create a highly differentiated value proposition for pharmaceutical, biotech, and academic organizations involved in early-stage development programs. According to Kate Briant, a Senior Partner at CapVest, these investments are fueled by confidence in Perceptive Discovery’s leadership and scientific teams, as they are expected to play an influential role in the oncology and radiopharmaceutical market segments, which is projected to grow significantly in the coming years.
About Perceptive Discovery
Perceptive Discovery provides advanced preclinical and translational solutions that seamlessly connect scientific innovation with early-phase clinical success. With expertise across various domains, including radiochemistry, in-vivo imaging, and radioligand therapy, the company is committed to generating high-quality, decision-ready data for partners in the biotech and pharmaceutical industries.
Frequently Asked Questions
What is Perceptive Discovery's recent investment for?
The recent $15 million investment is to enhance their radiochemistry, cell assay, and in vitro capabilities.
How will the Astatine-211 infrastructure improve operations?
This expansion will allow better support and delivery of alpha-emitting isotopes necessary for innovative therapies.
What new capabilities are being added for cell assays?
Perceptive Discovery is adding in-house hot assay development to streamline its scientific workflows.
What major upgrades are planned for the in vitro biology facility?
The facility upgrades will include increased laboratory space, new equipment, and expert personnel to enhance research capabilities.
How does Perceptive Discovery position itself in the market?
Perceptive Discovery aims to provide unique value for pharma and biotech organizations engaged in early development through its integrated workflows.
